Life Sciences, Biotechnology and Diagnostics Segment — Impairment Charges
Danaher Life Sciences, Biotechnology and Diagnostics Segment — Impairment Charges remained flat by 0.0% to $32.50M in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase in impairment charges signals that the company has identified a decline in the expected future cash flows or market value of its assets, often suggesting poor performance of past acquisitions or technological obsolescence. A decrease or absence of charges suggests that the segment's assets are performing in line with or exceeding their carrying value expectations.
Detailed definition
This metric represents the non-cash expense recognized when the carrying value of long-lived assets, such as goodwill, i...
Peer comparison
Peers in the life sciences and diagnostics sector typically report these charges periodically following large-scale M&A activity, with high-performing companies maintaining minimal impairment levels relative to their total asset base.
dhr_segment_life_sciences_biotechnology_and_diagnostics_segment_impairment_chargesHistorical Data
| FY'25 | |
|---|---|
| Value | $130.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's life sciences, biotechnology and diagnostics segment — impairment charges?
- Danaher (DHR) reported life sciences, biotechnology and diagnostics segment — impairment charges of $32.50M in Q4 2025.
- What does life sciences, biotechnology and diagnostics segment — impairment charges mean?
- The amount of value written off from assets in the life sciences and diagnostics business because they are no longer worth as much as previously recorded.